Immunovant Halts IMVT-1402 Lupus Program Following Trial Failure

Key Facts

Immunovant halted the development of IMVT-1402 for cutaneous lupus erythematosus after it failed to meet its primary goal. Zacks reported that the company officially terminated the program following disappointing clinical trial results, as the drug candidate did not reach its primary efficacy endpoint.

IMVT closed at $34.54 on September 23, 2026, with the stock trading between a low of $33.6 and a high of $37 during that session. The company intends to prioritize other pipeline assets, noting that the termination occurred despite the drug maintaining a clean safety profile throughout the trials.